From July to September, our research team reviewed published clinical outcomes data, federal OUD treatment statistics, and Michigan state health reports. Rapid opioid detox procedure completion rates run between 82% and 98%, but 6-month abstinence rates without structured aftercare average approximately 15%, rising to 36% or higher with extended-release naltrexone. How success is defined, and what aftercare follows discharge, determines outcomes more than the detox procedure itself.

This report breaks down rapid opioid detox success rates by outcome metric, time point, aftercare type, substance history, plus Michigan opioid treatment data.

Rapid Opioid Detox Success Rate by Outcome Metric: 2026

The table below breaks down the core outcome metrics used to measure rapid opioid detox success.

Outcome Metric Published Rate
Detox procedure completion 82-98%
Opioid-free at discharge ~95%+
30-day abstinence (no aftercare) ~36%
6-month abstinence (no aftercare) ~15%
6-month abstinence (with Vivitrol) ~36%
12-week treatment program completion ~18-30%
Opioid relapse within 1 year (any detox method) 80-91%
Relapse on day of discharge or within 1 week ~25%
Naltrexone initiation rate (supervised programs) ~98%
Naltrexone initiation rate (real-world settings) ~63%
Adults nationally receiving MOUD after detox 25%

The data reveals that procedure completion and long-term abstinence measure two different things. Most patients complete the medical detox procedure, but the majority relapse within 12 months without extended aftercare. The critical divergence happens in the first 30 days, where patients without a structured follow-up plan account for the largest share of early relapses.

Rapid Opioid Detox Success Rate by Time Point: 2026

The table below breaks down published abstinence rates at each major follow-up interval from discharge.

Time Point Abstinence Rate (No Aftercare) Abstinence Rate (With Naltrexone Aftercare)
At discharge ~95%+ ~95%+
30 days ~36% ~55-65%
90 days ~25-36% ~45-55%
6 months ~15% ~36-53%
12 months ~10-20% ~25-35%

The data shows a steep and consistent decline in abstinence rates over time when no aftercare is in place, with the steepest drop occurring between discharge and the 30-day mark. Naltrexone-based aftercare narrows this decline at every interval, with the benefit most pronounced at 6 months, where the gap between aftercare and no-aftercare outcomes is widest.

Rapid Opioid Detox Success Rate by Aftercare Type: 2026

The table below breaks down published abstinence outcomes by the type of aftercare received following rapid opioid detox.

Aftercare Approach 30-Day Abstinence 6-Month Abstinence
No structured aftercare ~36% ~15%
Oral naltrexone (daily) ~40-50% ~25-30%
Extended-release naltrexone (Vivitrol, monthly) ~55-65% ~36%
Vivitrol + physician-managed follow-up ~60-70% ~40-53%
Non-medication-based treatment only Below MOUD outcomes Below MOUD outcomes

The data reveals that the delivery format of naltrexone matters as much as the medication itself. Shifting from a daily oral dose to a monthly injection removes the daily compliance variable, which is the primary driver of dropout in oral naltrexone programs. Physician-managed follow-up with direct access to the treating provider produces the strongest outcomes at both the 30-day and 6-month marks.

Rapid Opioid Detox Success Rate by Substance Type: 2026

The table below breaks down how patient opioid history affects the likelihood of completing detox and entering sustained recovery.

Substance History Effect on Detox Outcomes
Prescription opioid primary use ~85% more likely to complete detox successfully than heroin users
Heroin primary use Lower completion and sustained abstinence rates across cohort studies
Fentanyl-involved use Elevated withdrawal complexity; higher medical supervision requirements
Polysubstance use Associated with lower treatment retention at every follow-up interval
Single-substance opioid dependence Associated with higher program completion and aftercare engagement

The data reveals that prescription opioid users have meaningfully better detox completion odds than heroin users, a difference that published research links to tolerance patterns, drug availability, and prior contact with the healthcare system. Fentanyl’s growing presence in Michigan’s drug supply adds withdrawal complexity that makes physician-supervised rapid detox more clinically relevant than in prior eras of the opioid crisis.

Michigan Opioid Treatment Data: 2026

The table below breaks down Michigan’s current opioid use disorder and treatment landscape.

Metric Michigan Data
Adult OUD prevalence 3.2% (vs. 2.5% national average)
Opioid overdose deaths, 2024 1,342 (down 41% from 2,287 in 2023)
Projected overdose death rate, 2025 16.4 per 100,000 (down from 30.8 in 2021)
Fentanyl share of overdose deaths 68%
OUD patients receiving timely evidence-based care 35%
Medicaid-insured OUD patients receiving any treatment 46%
Estimated economic toll of opioid crisis $41.4 billion
Naloxone kits distributed statewide 1.8 million

The data shows that Michigan carries a higher OUD prevalence than the national average while simultaneously running a treatment access rate roughly 10 percentage points below it. Despite the state’s 47% decline in overdose deaths since 2021, the majority of Michigan residents who need opioid use disorder treatment are not receiving it. Rapid-entry programs that can complete the medical detox phase in days rather than weeks address a meaningful portion of that gap.

Contact All Opiates Detox

For more information about rapid opiate detox in Wyandotte, Michigan, contact All Opiates Detox.

Contact All Opiates Detox to speak directly with Dr. Joseph George, MD, at (800) 458-8130.

Sources